annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
Brd. 9F What part does sleep disturbance play in post-cancer fatigue? Findings from
a prospective cohort study. (Abstract #605)
B. K. Bennett, D. Goldstein, F. M. Boyle, P. L. De Souza, N. Wilcken,
M. Friedlander, I. Hickie, E. Scott, N. Rogers, A. R. Lloyd
Brd. 9G HER2 testing: A health economics perspective on alternative test strategies.
(Abstract #606)
J. A. Lee, M. F. Press
Brd. 9H Residual cancer burden (RCB) in breast cancer patients treated with taxaneand
anthracycline-based neoadjuvant chemotherapy: The effect of race.
(Abstract #607)
M. Chavez-Mac Gregor, R. Hubbard, F. Meric-Bernstam, S. S. Shinde, J. K. Litton,
W. A. Woodward, V. Valero, G. N. Hortobagyi, W. F. Symmans, A. M. Gonzalez-
Angulo
Brd. 10A Expression of forkhead-box protein A1 (FOXA1) as a significant prognostic
and predictive marker for ER-positive breast cancer. (Abstract #608)
E. Tokunaga, Y. Hisamatsu, S. Okada, N. Yamashita, Y. Nakashima, H. Saeki,
Y. Emi, M. Morita, Y. Kakeji, Y. Maehara
Brd. 10B The influence of mammaplasty in axillary lymphatic drainage patterns and
sentinel lymph node detection. (Abstract #609)
C. Bouteille, C. Soler, A. Steiner, B. Geissler, E. Gremillet
Brd. 10C Effect of neoadjuvant alternating taxane- and anthracycline-based dosedense
regimen for operable breast cancer on prognosis in triple-negative
tumors with a complete histological response. (Abstract #610)
J. Medioni, C. Huchon, M. le Frere-Belda, H. Hoffman, A. Bats, D. Eme, J. Andrieu,
S. Oudard, E. Levy, F. Lecuru
Brd. 10D Nuclear NF-kb/p65 expression and response to neoadjuvant chemotherapy
in breast cancer. (Abstract #611)
R. L. Jones, F. G. Rojo, R. A’Hern, N. Villena, J. Corominas, S. Servitja, A. Rovira,
J. S. Reis-Filho, M. Dowsett, J. Albanell
Brd. 10E Breast cancer patients access to screening, radiotherapy, and cancer drugs
in 18 European, Asian, and Latin American countries. (Abstract #612)
N. E. Wilking, J. Bergh, B. Jönsson, F. Kasteng
Brd. 10F The impact of the radiotherapy boost in ductal carcinoma in situ. (Abstract
#613)
P. Wong, C. Lambert, R. V. Agnihotram, M. David, M. Duclos, C. Maietta,
E. Pietracupa, C. R. Freeman
Brd. 10G Cost-effectiveness of adjuvant systemic therapy in early-stage breast cancer
patients with isolated tumor cells or micrometastases in regional lymph
nodes. (Abstract #614)
M. De Boer, E. M. Adang, K. C. Van Dycke, J. A. Van Dijck, G. F. Borm,
C. H. Van Deurzen, P. J. Van Diest, P. Bult, A. T. Donders, V. C. Tjan-Heijnen
Brd. 10H Use of adjuvant trastuzumab with chemotherapy in women with small,
node-negative, HER2-positive breast cancers. (Abstract #615)
H. L. McArthur, K. Mahoney, P. G. Morris, S. Patil, L. M. Jacks, J. Howard,
L. Norton, C. Hudis
Brd. 11A Substituting doxorubicin with nonpegylated liposomal doxorubicin (NPLD) in
adjuvant/primary chemotherapy for early breast cancer, impact in cardiac
function: A pilot study. (Abstract #616)
N. Davidson, A. Chalkidou, D. Houghton
Brd. 11B Positron emission tomography (PET) and estrogen receptor (ER) ligand in
patients with invasive breast cancer. (Abstract #617)
M. Gemignani, S. Patil, E. Brogi, S. M. Larson, M. Morrow, N. Pandit-Taskar
Brd. 11F Notch and Jak/STAT signaling pathways in breast carcinoma of luminal and
basal/triple-negative immunophenotypes. (Abstract #618)
E. Adrover, L. Sanchez-Tejada, G. Peiro, D. Giner, E. Lerma, F. I. Aranda,
F. J. Gutierrez-Aviño
152